BRCA2 and cancer: Another possible alternative is PARPis, which emerged as a breakthrough therapeutic strategy in the early 2000s22 by exploiting the defects in BRCA1 and BRCA2. Until then, mutations in those genes were considered a cancer prophecy waiting to happen, but PARPis transformed a bad omen into a therapeutic opportunity.